Placenta plays a very significant role in the development of secretory and regulatory functions for the maintenance of pregnancy and in the nutrition of the embryo. It shares many functions of the heart, lung, liver, endocrines, and other organs. In Placental Pharmacology, fourteen expert authors discuss how placenta and its component parts can be used effectively in drug development research and in the study of transfer mechanisms across membranes. This reference begins by describing the use of modern biophysical methods to study placental function and prospects for their application in pharmacological research. The next three chapters deal with placental hemodynamics, use of placental tissues and cells in pharmacological assays, and placental transfer of drugs used in pregnancy. Three more chapters contain up-to-date information on molecular biological aspects of placenta currently receiving lots of attention - phospholipase A2 isozymes, imprinted genes and embryogenesis, and placental growth factors. The final chapter describes the clinically relevant topics of placental metabolism and toxicity of homocysteine in placenta. Easy to understand, thorough, and complete, Placental Pharmacology is the perfect resource for scientists interested in placenta and its uses in drug development and testing.

Placental Toxicology examines placental transfer and toxicology of drugs and environmental agents to placenta, as well as to fetus. For the first time in a single volume, placental and fetal consequences of exposure of pregnant women to drugs, environmental chemicals, and infections, such as HIV, are discussed. Topics include: The art of in

This textbook provides an up-to-date summary of the scientific basis, assessment for and provision of anaesthesia throughout pregnancy and labour. It is divided into nine sections including physiology, assessment, complications and systemic disease.

Placental Toxicology examines placental transfer and toxicology of drugs and environmental agents to placenta, as well as to fetus. For the first time in a single volume, placental and fetal consequences of exposure of pregnant women to drugs, environmental chemicals, and infections, such as HIV, are discussed. Topics include: The art of in vitro perfusion of human placenta Abuse of alcohol, nicotine, morphine, and cocaine during pregnancy, their placental transfer and fetal growth retardation Placental transfer and fetal toxicities of environmental insecticides Placental hormones and fetal well-being Placental transfer of HIV and treatment of pregnant women with anti-HIV drugs

The second edition of Fundamentals of Anaesthesia builds upon the success of the first edition, and encapsulates the modern practice of anaesthesia in a single volume. Written and edited by a team of expert contributors, it provides a comprehensive but easily readable account of all of the information required by the FRCA Primary examination candidate and has been expanded to include more detail on all topics and to include new topics now covered in the examination. As with the previous edition, presentation of information is clear and concise, with the use of lists, tables, summary boxes and line illustrations where necessary to highlight important information and aid the understanding of complex topics. Great care has been taken to ensure an unrivalled consistency of style and presentation throughout.

Medication use during pregnancy requires a balance between treating a condition in the mother, and minimizing potential risks in the fetus. In recent years, it has been estimated that between 50 and 70% of pregnant women in North America will take at least one prescription medication during their pregnancy. The decision to begin or continue treatment during pregnancy relies heavily on evaluating the risk-benefit ratio, and an important determinant in this risk assessment is estimating fetal drug exposure. The use of medications in pregnant women can be especially challenging, as there is very limited safety data in pregnancy. Recently, novel oral anticoagulants have been developed and approved for clinical use. However, the information regarding their fetal safety and placental transfer in humans is unknown. We used the ex vivo placenta perfusion model to investigate anticoagulant (dabigatran, rivaroxaban, apixaban) transfer across the human placenta. Rivaroxaban and apixaban rapidly crossed the term human placenta, while dabigatran crossed the placenta to a lesser extent. The placenta perfusion results were adjusted to account for protein binding and pH differences between the mother and fetus. We also developed a pharmacokinetic model that adequately described the transplacental transfer of anticoagulants by using data from our experiments. While the placenta perfusion model can be technically challenging, its results strongly correlate with in vivo placental transfer data. By evaluating the success rate of the perfusion model in our laboratory, we determined that establishing the fetal circulation is an important stage of the protocol. This information can be used to create a focused training program to help increase the overall success rate of this model and productivity of the lab. Drug use in pregnancy is multifactorial, and placental transfer data is important in assessing which drugs can be used to treat the mother while protecting the unborn.